Literature DB >> 28805095

Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

Tony Sehr1, Undine Proschmann1, Katja Thomas1, Tjalf Ziemssen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28805095     DOI： 10.1177/1352458517726384

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  1 in total

1.  Response to "Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing".

Authors:  Zoé LE van Kempen; Theo Rispens; Joep Killestein
Journal:  Mult Scler       Date:  2017-10-09       Impact factor: 6.312
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.